These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26502580)

  • 1. [Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma].
    Van Daele D; Puleo F; Dumont R; Polus M; Loly C; Martinive P; Meunier P; Collignon J; Hendlisz A; Maréchal R; Louis E; Van Laethem JL
    Rev Med Suisse; 2015 Aug; 11(483):1543-8. PubMed ID: 26502580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
    Winner M; Goff SL; Chabot JA
    Semin Oncol; 2015 Feb; 42(1):86-97. PubMed ID: 25726054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CRITICAL VIEWPOINT ON THE CURRENT APPROACH OF LOCALIZED PANCREATIC DUCTAL ADENOCARCINOMA].
    Van Daele D; Martinive P; Loly C; Polus M; Collignon J; Gast P; Louis E; Van Laethem JL
    Rev Med Liege; 2015 Nov; 70(11):540-5. PubMed ID: 26738264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
    Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
    Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
    Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
    Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Ferrone CR
    Dig Surg; 2016; 33(4):343-50. PubMed ID: 27216011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
    Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
    Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
    Tesfaye AA; Philip PA
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving pancreatic cancer treatment: From diagnosis to healthcare management.
    Milella M; Bassi C; Boggi U; Brunetti O; Cavaliere A; Crippa S; De Vita F; Falconi M; Frassineti GL; Giommoni E; Macchini M; Malleo G; Silvestris N; Tudisco A; Vasile E; Reni M
    Crit Rev Oncol Hematol; 2022 Jan; 169():103571. PubMed ID: 34923121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
    JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
    Silvestris N; Brunetti O; Vasile E; Cellini F; Cataldo I; Pusceddu V; Cattaneo M; Partelli S; Scartozzi M; Aprile G; Casadei Gardini A; Morganti AG; Valentini V; Scarpa A; Falconi M; Calabrese A; Lorusso V; Reni M; Cascinu S
    Crit Rev Oncol Hematol; 2017 Mar; 111():152-165. PubMed ID: 28259290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment for pancreatic ductal carcinoma.
    Macarulla T; Fernández T; Gallardo ME; Hernando O; López AM; Hidalgo M
    Clin Transl Oncol; 2017 Oct; 19(10):1199-1204. PubMed ID: 28639051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of extracapsular lymph node involvement in pancreatic ductal adenocarcinoma.
    Sergeant G; Ectors N; Fieuws S; Aerts R; Topal B
    Ann Surg Oncol; 2009 Nov; 16(11):3070-9. PubMed ID: 19649555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
    Álvarez R; Alés I; Díaz R; de Paredes BG; Hidalgo M
    Clin Transl Oncol; 2017 Oct; 19(10):1193-1198. PubMed ID: 28612203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 20. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
    Kang CM; Hwang HK; Choi SH; Lee WJ
    Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.